Managing Viral Hepatitis in Cancer Patients Under Immune Checkpoint Inhibitors: Should we Take the Risk?

References

• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Dyck L , MillsKHG. Highlights mini-review: Immune checkpoints and their inhibition in cancer and infectious diseases. Eur. J. Immunol.47, 765–779 (2017).
   PubMed Web of Science ®Google Scholar
• Michot JM , BigenwaldC , ChampiatSet al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer54, 139–148 (2016).
   PubMed Web of Science ®Google Scholar
• Johnson DB , SullivanRJ , MenziesAM. Immune checkpoint inhibitors in challenging populations. Cancer123(11), 1904–1911 (2017).
   PubMed Web of Science ®Google Scholar
• De Bruyn P , Van VlierbergheH , LeMoine Aet al. Immune checkpoint blockade for organ transplant patients with advanced cancer. Curr. Opin. Oncol.31(2), 54–64 (2019).
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N , ShahM , Lopez-OlivoMA , Suarez-AlmazorME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann. Intern. Med.168(2), 121 (2018).
   PubMed Web of Science ®Google Scholar
• Daste A , DomblidesC , Gross-goupilMet al. Immune checkpoint inhibitors and elderly people: a review. Eur. J. Cancer82, 155–166 (2017).
   PubMed Web of Science ®Google Scholar
• Thio CL , MosbrugerTL , KaslowRAet al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J. Virol.78(20), 11258–11262 (2004).
   PubMed Web of Science ®Google Scholar
• Fromentin R , BakemanW , LawaniMBet al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog.12(7), e1005761 (2016).
   PubMed Web of Science ®Google Scholar
• Kaufmann DE , WalkerBD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J. Immunol.182(10), 5891–5897 (2009).
   PubMed Web of Science ®Google Scholar
• Chew GM , FujitaT , WebbGMet al. TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection. PLOS Pathog.12(1), e1005349 (2016).
   PubMed Web of Science ®Google Scholar
• Boyer Z , PalmerS. Targeting immune checkpoint molecules to eliminate latent HIV. Front. Immunol.9, 2339 (2018).
   PubMed Web of Science ®Google Scholar
• Nguyen LT , OhashiPS. Clinical blockade of PD1 and LAG3 – potential mechanisms of action. Nat. Rev. Immunol.15(1), 45–56 (2015).
   PubMed Web of Science ®Google Scholar
• Fujita K , KimYH , KanaiO , YoshidaH , MioT , HiraiT. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir. Med.146, 66–70 (2019).
   PubMed Web of Science ®Google Scholar
• Makarova-Rusher OV , Medina-EcheverzJ , DuffyAG , GretenTF. The yin and yang of evasion and immune activation in HCC. J. Hepatol.62 (6), 1420–1429 (2015).
   PubMed Web of Science ®Google Scholar
• Wykes MN , LewinSR. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol.18(2), 91–104 (2018).
   PubMed Web of Science ®Google Scholar
• Del Castillo M , RomeroFA , ArgüelloE , KyiC , PostowMA , Redelman-SidiG. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis.63(11), 1490–1493 (2016).
   PubMed Web of Science ®Google Scholar
• Cook MR , KimC. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol.5(7),1049–1054 (2019).
   PubMed Web of Science ®Google Scholar
• Knolle PA , WohlleberD. Immunological functions of liver sinusoidal endothelial cells, Chinese Soc Immunology. Cell. Mol. Immunol.13, 347–353 (2016).
   PubMed Web of Science ®Google Scholar
• Elsegood CL , Tirnitz-ParkerJE , OlynykJK , YeohGC. Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clin. Transl. Immunol.6(11), e161 (2017).
   PubMedGoogle Scholar
• Loomba R , LiangTJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology152(6), 1297–1309 (2017).
   PubMed Web of Science ®Google Scholar
• Ravi S , SpencerK , RuisiMet al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J. Immunother. Cancer2(1), 33 (2014).
   PubMedGoogle Scholar
• Riezu-Boj J-I , LarreaE , AldabeRet al. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J. Hepatol.54(3), 422–431 (2011).
   PubMed Web of Science ®Google Scholar
• Lok ASF , LiangRHS , ChiuEKW , WongK-L , ChanT-K , ToddD. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology100(1), 182–188 (1991).
   PubMed Web of Science ®Google Scholar
• Alexopoulos CG , VaslamatzisM , HatzidimitriouG. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br. J. Cancer81(1), 69 (1999).
   PubMed Web of Science ®Google Scholar
• Law JK , HoJK , HoskinsPJ , ErbSR , SteinbrecherUP , YoshidaEM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk. Lymphoma46(7), 1085–1089 (2005).
   PubMed Web of Science ®Google Scholar
• Blackard JT , ShermanKE. Hepatitis B virus (HBV) reactivation – the potential role of direct-acting agents for hepatitis C virus (HCV). Reviews in Medical Virology John Wiley and Sons Ltd, 28(4), 1984 (2018).
   Web of Science ®Google Scholar
• Myint A , TongMJ , BeavenSW. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin. Liver Dis.15(4), 162–167 (2020).
   Google Scholar
• Loomba R , LiangTJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology152(6), 1297–1309 (2017).
   PubMed Web of Science ®Google Scholar
• Visram A , FeldJJ. Defining and grading HBV reactivation. Clin. Liver Dis.5(2), 35–38 (2015).
   Google Scholar
• Torres HA , HosryJ , MahaleP , EconomidesMP , JiangY , LokAS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology67(1), 36–47 (2018).
   PubMed Web of Science ®Google Scholar
• Chascsa DM , RakelaJ. Knowns and unknowns: the safety and efficacy of cancer immunotherapy in chronic liver disease. Curr. Hepatol. Reports17(3), 153–155 (2018).
   Google Scholar
• Rai R , EzeokeOM , McQuadeJLet al. 1148PDImmunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. Ann. Oncol.28, 1148 (2017).
   Web of Science ®Google Scholar
• Sangro B , Gomez-MartinC , dela Mata Met al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol.59(1), 81–88 (2013).
   PubMed Web of Science ®Google Scholar
• Hosry J , NaingA , TorresH. 2226. Immune checkpoint inhibitors in solid tumor patients with chronic hepatitis C virus infection: a prospective case-series. Open Forum Infect. Dis.5(Suppl. 1), S658–S658 (2018).
   Google Scholar
• Tio M , RaiR , EzeokeOMet al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur. J. Cancer104, 137–144 (2018).
   PubMed Web of Science ®Google Scholar
• Wen X , DingY , ZhuBet al. Seroconversion of Hbsag in melanoma patient with hepatitis B treated with checkpoint inhibitors: a case report. J. Clin. Case Rep.7, 951 (2017).
   Google Scholar
• Koksal AS , TokaB , EminlerAT , Hacibekirogluİ , UslanMI , ParlakE. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann. Oncol.28(12), 3103–3104 (2017).
   PubMed Web of Science ®Google Scholar
• Shah NJ , Al-ShboolG , BlackburnMet al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J. Immunother. Cancer7(1), 1–8 (2019).
   PubMed Web of Science ®Google Scholar
• Wen X , WangY , DingYet al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Res.26(3), 284–289 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang X , ZhouY , ChenCet al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J. Immunother. Cancer7(1), 1–10 (2019).
   PubMed Web of Science ®Google Scholar
• Davar D , WilsonM , PrucknerC , KirkwoodJM. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep. Oncol. Med.2015, 1–5 (2015).
   Google Scholar
• Liu X , QinS , QinS. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges. Oncologist24(Suppl. 1), S3–S10 (2019).
   PubMed Web of Science ®Google Scholar
• Xu F , JinT , ZhuY , DaiC. Immune checkpoint therapy in liver cancer. J. Exp. Clin. Cancer Res.37(1), 110 (2018).
   PubMed Web of Science ®Google Scholar
• Kudo M . Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology92(1), 50–62 (2017).
   PubMedGoogle Scholar
• Fisicaro P , ValdattaC , MassariMet al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology138(2), 682–693.e4 (2010).
   PubMed Web of Science ®Google Scholar
• Bengsch B , MartinB , ThimmeR. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol.61(6), 1212–1219 (2014).
   PubMed Web of Science ®Google Scholar
• Shi F , ShiM , ZengZet al. PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer.128(4), 887–896 (2011).
   PubMed Web of Science ®Google Scholar
• Wang B , MuftiG , AgarwalK. Reactivation of hepatitis B virus infection in patients with hematologic disorders, Ferrata Storti Foundation. Haematologica104(3), 435–443 (2019).
   PubMed Web of Science ®Google Scholar
• Regev A , AviganMI , KiazandAet al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J. Autoimmun.114, 102514 (2020).
   PubMed Web of Science ®Google Scholar
• Pattullo V . Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J. Hepatol.7(7), 954–967 (2015).
   PubMedGoogle Scholar
• Lee HL , BaeSH , JangBet al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver11(6), 870–877 (2017).
   PubMed Web of Science ®Google Scholar